Patients with type 2 diabetes and diabetic peripheral neuropathy may have an increased time to first opioid request and reduced time to onset of sensory blockade after an ultrasound-guided popliteal sciatic nerve block compared with patients without neuropathy.
A sustained-release formulation of sodium nitrite may not be associated with headaches and dizziness reported by patients treated with the immediate-release formulation of sodium nitrite for diabetic peripheral neuropathy.
Investigators hypothesize that needle and laser acupuncture may improve clinical and subjective symptoms in patients with diabetic peripheral neuropathy.
The type of sciatic nerve lesions observed in patients with diabetic peripheral neuropathy was found to differ in type 1 and type 2 diabetes.
The presence of diabetes — both types 1 and 2 — may be associated with a reduced risk for migraine
Oral vitamin E supplementation consisting of 400 mg/day mixed tocotrienols for 1 year may not result in improved neuropathic pain symptoms in patients with diabetic peripheral neuropathy.
A recent study assessed the relationship of fasting neuropeptide Y with insulin resistance, β-cell function, and glucagon-like peptide-1 secretion in patients with migraine.
Results from a study investigating diabetes and migraine in the Norwegian population show that type 1 and type 2 diabetes were significantly associated with a decreased risk for migraine.
Evidence for the effectiveness of oxcarbazepine in painful diabetic neuropathy and other forms of neuropathic pain is limited.
Dr Cuevas-Trisan covered the evaluation and management of diabetic peripheral neuropathic pain during his presentation at PAINWeek 2017.
